Analysis of Curcumin as a Radiosensitizer in Cancer Therapy with Serum Survivin Examination: Randomised Control Trial.

Yudi Mulyana Hidayat, Frank Wagey, Dodi Suardi, Herman Susanto, Bismarck J Laihad, Maringan Diapari Lumban Tobing

Journal: Asian Pacific journal of cancer prevention : APJCP 2021;22(1):139-143

PMID: 33507691

Abstract

OBJECTIVE

One of the important treatments for cervical cancer is radiation therapy. This study sought to determine the role of curcumin as a radio-sensitizing agent for use with radiation therapy for cervical cancer. To accomplish this, we assessed the levels of survivin, which is an anti-apoptotic protein that plays a role in cell division and apoptosis inhibition.

METHOD

This study used a quasi-experimental design, including a pretest-posttest control group design approach. The study subjects included cervical carcinoma stage IIB-IIIB patients who were scheduled to undergo surgery at the Hasan Sadikin Hospital Bandung during the research period. The advanced cervical cancer patients were assigned to two groups: i) those who received curcumin + radiation therapy and ii) those who received placebo + radiation therapy.

RESULTS

In the group treated with curcumin + radiation, 15 (75%) patients showed decreased survivin levels and 5 (25%) showed increased survivin levels. Whereas, in the placebo + radiation group, there were 8 (40%) patients who showed decreased survivin levels and 12 (60%) who showed increased survivin levels.

CONCLUSION

In conclusion, curcumin is an effective, alternative radiosensitizer agent for application in cervical cancer treatment.
.

Address: Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjajaran, Bandung, Indonesia.; Department of Obstetrics and Gynecology, School of Medicine, Universitas Sam Ratulangi, Manado, Indonesia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.